for report revenue, third Good which increases quarter strong pleased today. year-over-year margin. afternoon, We're us Frank. joining you, in everyone, gross performance, includes thank and volume you Thank to
of XXXX. and quarter For $XX.X the on in million third quarter, reported increase of the $XX.X million revenue we third
during X,XXX XXXX driver, we our growth the Our provided our of with reports XX%. quarter test growth XXXX of primary compared representing third third reports of in test, quarter DecisionDx-Melanoma X,XXX
clinicians at continue September Additionally, we to quarter third the of demonstrate 'XX to for of XX% XXXX. new ordering in growth compared
our XXXX XXXX, clinicians, note X% of is the new For that compared third further quarter growth in we a a to substantial. the in jump third to quarter comparison of saw so XX% ordering growth
Overall, expression we XX% proprietary delivered representing DecisionDx-Melanoma overall third gene of XXXX and tests profile during X,XXX compared for quarter third reports to quarter DecisionDx-UM the XXXX. growth of the
our development expansion growth our DecisionDx-Melanoma continue As increase, of test ongoing excellent both see you to and following our evidence. from commercial XXXX quarter can see we volume first
recall with of sales the You associated the in sales quarter personnel. to may that first XXXX, the XX XX outside from commercial our along and medical for increase number headcount we territory of
decided plans As this third we XX we XXXX outside have nine expansion additional growth sales these sales staff additional second territories a We December acceleration quarter and year, in execute result commercial plan higher outside will quarter and and in nine, medical our accordingly. additional of commercial now the affairs the of territories. to add and to
for reports XXX the melanoma tests, period uveal quarter in our DecisionDx-UN a year. increase during same test XXXX, Turning last we delivered third XX% patients the
XXXX. first melanoma were with uveal XXXX, volumes up the ended For X% period report September months test same nine compared in XX,
in of a diagnosed we currently As reminder, test more patients melanoma with test our newly patients the and the DecisionDx-UM estimated, uveal U.S. standard-of-care XX% for is diagnosed than
to highlights to third Now several I from turn like our would quarter. significant
these suspicious total pigmented our of for that commercial We our remain to pipeline who launch two on market billion. second our addressable XXXX approximately and We products lesions. carcinoma cell pipeline estimated by squamous U.S. will of $X.X pipeline for cutaneous track First high-risk late-stage for is believe new localized, patients tests half products with increase two our for products. DecisionDx-SCC relates diagnosed
this in each is for Regarding data due patients melanoma; incident reported study with of year die from cancer instance million diagnosed this risk and October's historically the XX,XXX called clinical from will SCC. will SCC approximately at has We Meeting test high-risk who Society the DecisionDx-SCC, validation diagnosed we are rate, year, growing. for that overall patients the the American Surgery, a Dermatologic in squamous carcinoma also than use X approximately skin estimate relative estimated SCC been lower during from for high is to the viewed as die with it cutaneous melanoma. U.S continuous however, patients localized, cell SCC high risk Annual with more -- SCC to
So, the historically of than benign, skin form aggressive most the lower-risk death disease today contributes more cancer.
XXX cell Our more clinical high-risk or patients approximately or focused patient We identified currently who believe more the use is should or squamous one with having carcinoma high-risk pathologic be on or appropriate focused one on features. features. as cutaneous pathologic
and patients test Now, believe decisions. about between our plans differences plan treatment treat impact where let's talk the and low-and we high-risk in
Currently, of as one Treatment neoadjuvant chemotherapy, treatment clinical risk active a neoadjuvant of surveillance radiation, categorizations. trial enrollment National novel process versus having same of risk clinical high different to defined plans with while as pathologic differences cutaneous Low staging, or no patients is features having features. upon more use cell use defined localized recommendations. plan these squamous include Guidelines defined low-risk based for Cancer two and is high-risk use carcinoma, high risk of
is majority plans of may Positive and therefore don't Value don't systems This they based need clinical having high-risk of patients their is plan, they staging aggressive as PPD will disease do benefit from. on the metastasize. the treatment not actually Predictive identified available position high-risk That in undergoing majority or low. of be The patients the issue say go that to means in is that to patients
would high-risk a goal development out these enable gene profile Our that de-escalation a expression is rule in test for to will patients. approach identify
algorithm able the training the develop then training cohort, to our assistance an the of XXX team independent to we're based cohort of cohort, I'm centers a complete clinical upon XX U.S., that and say patients. study lock pleased R&D the validation with gene, set active in
National Importantly, risk who cohort Cancer validation by or XX% criteria. risk Comprehensive Network the high of NCCN all patients are
So cohort so we our use the criteria our appropriate mirrors population validation DecisionDx-SCC believe test. for the meet
test result the for and the The data staging compared risk Surgery test XX.X% DecisionDx-SCC Class a a for of Cancer SCC The Class Negative Brigham Xb Value for Society PPV DecisionDx-SCC for for system, XX.X% for NPV X American result was Predictive as on results XX.X% Women's Dermatologic risk Hospital highest XX%, system, Joint XX.X%. this staging Committee to and shown American or presented criteria. PPV the in the
result who Class X for with XX% a meaning XX% test Regarding a the and as the high had Class Xb tumor to proceed potential clinical clinical lowest-risk clinician impact care provides could objective forward the recommendations tests, clinician patients risk risk include confidently And adjuvant with implementing trial a with deescalating radiation or DecisionDx may data approximately that the highest SCC noted plan of patients. in chemotherapy high-risk test of treatment result, earlier. consider
Biosciences. Validation through tests have a one the The do a this We tests. test both cancers working second these by pigmented cancer studies the time. total XX update are who last This DecisionDx-SCC our lesion. with targeted have ongoing prospective of data at validated DecisionDx-SCC study studies a are third and centers U.S. with for initial not patient suspicious test study. and skin skin performance discovered, Castle underway including for a month, developed is engaged late We validation us in
second DecisionDx However, of launch in pending XXXX. to validation we and pigmented the position successful lesion half that continue are the the in to believe both SCC suspicious tests tests
DecisionDx-Melanoma Lastly, in the saw to third commercial and of by continued our we publication evidence quarter, payers. test use appropriate covers support
of of of expression Clinical by test peer evidence the for gene in was One profile of review literature for Journal establish objective Danielle The study for cutaneous American melanoma. level studies to of Dermatology seven peer validation and was published and A reviewed Dubin colleagues DecisionDx-Melanoma review title evidence was these reviewed development level in of for the the conducted. and published DecisionDx-Melanoma.
that the study Cancer, American to test management of strengths, that published the on and criteria Joint the the National of published each of for guidelines major the this evidence level were evidence including Network each than which based Academy evaluation the Dermatology, all or NCCN, DecisionDx-Melanoma higher by manuscript evidence these groups. shows Cancer a the determined upon applied American melanoma Committee achieves to the level one respective Comprehensive of of from The organizations
the between Of note the timing and Dr. both or the one is its achieved to in February evidence the uses of May inclusion brings peer current published clinically actively the or level that the due was three XX that of XXXX. DecisionDx-Melanoma publications two studies Dubin's reviewed prospective This to without benefit of test. analysis total manuscript number study of support of of of
to to is subsequent or on test and in is than when X equal tumor the clinical The biopsy guide of plan our first use thickness second the decisions clinical millimeters, is use decisions. inform less treatment patients
As we covered our Medical American previously supporting is CPT We penetration Panel, evidence commercial believe investment accepted continued our development and at key by category CPT of evidence the in patient received X January both test. Association, recently that DecisionDx-Melanoma a to notification application stated, payers. code MAAA code MAAA The levels we met for means X Category certain requirements. CPT on have attained XXXX, a for Xst will code effective be Editorial
on clinical evidence are to efficacy needed focused be documented the example, the in For literature, hence development.
use, be performed is with the many frequency Additionally, or of that current with practice, consistent test it intended use physicians medical is healthcare of and use a requires qualified with the other to by performed it professionals. consistent
of MAAA was DecisionDx-Melanoma X tests, The we the test criteria DecisionDx-Melanoma viewed these met both criteria, code. all DecisionDx-UM that with. CPT agree Category proprietary of for required at meeting our and which MAAA acceptance means have now Our
related turn to over provide will Frank the who will back results. to financial I additional call now our detail
